Before we dive into the mistakes, lets make sure were on the same page
It is not a drug or supplement
According to WTW data, the PMPM expenditure on these drugs for employers has increased exponentially
The different ones GI discontinuation rate: 5.6% of semaglutide (Wegovy) users stopped due to GI side effects, vs 2.7% of Tirzepatide (Mounjaro) users Diarrhoea: Common with Mounjaro because of its dual action Nausea and constipation: Seen more in Wegovy MHRA NAION warning (February 2026) : Both medications carry an updated warning about a very rare but serious eye condition (non-arteritic anterior ischaemic optic neuropathy)
In late 2023, the FDA explicitly flagged BPC-157 as a Category 2 substance, citing concerns about immune reactions, peptide impurities, and lack of safety data for human use
Does the Precision Peptide Genetic Test help with semaglutide dosing decisions